Interim data from Part A of REO 033 is expected by year-end 2026, which will be the first randomized readout for pelareorep in colorectal cancer. The FDA alignment on a potential accelerated approval pathway is a positive regulatory signal, but the stock will likely remain range-bound until hard clinical data is released.
Price Chart
Executive Summary
Oncolytics Biotech reported accelerating enrollment in its REO 033 Phase 2 study of pelareorep in RAS-mutant, MSS metastatic colorectal cancer. Nearly all planned clinical sites are activated, and the company expects an interim data update by year-end 2026. FDA alignment on a potential accelerated approval path based on objective response rate was also disclosed.
Key Facts
- Substantially all planned REO 033 clinical sites are now activated with multiple patients enrolled.
- Company expects sufficient Part A data for an interim clinical update by year-end 2026.
- FDA alignment provides a potential path to accelerated approval based on objective response rate and full approval based on progression-free survival.
- Part A of REO 033 is expected to enroll approximately 60 patients randomized 1:1 between pelareorep+FOLFIRI+bevacizumab vs FOLFIRI+bevacizumab.
- Prior non-randomized REO 022 study showed ORR of 33%, median PFS of 16.6 months, and median OS of 27.0 months vs historical benchmarks of 6-11%, 5.7 months, and 11.2 months respectively.
Financial Impact
No financial figures reported in the filing.
Risk Factors
- REO 022 data was from a small, non-randomized study and may not replicate in the randomized REO 033 trial.
- The company is pre-revenue and relies on capital markets for funding; no cash position or financing was disclosed in this filing.
- Enrollment and data timelines are forward-looking statements and may be delayed.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000057 |
| Document: oncolyticsreo033trialmomen.htm | 0001129928-26-000057 |
| Document: 0001129928-26-000057-index-headers.html | 0001129928-26-000057 |
| Document: 0001129928-26-000057-index.html | 0001129928-26-000057 |
| Document: 0001129928-26-000057.txt | 0001129928-26-000057 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $0.4986 | awaiting T+20 | — | $0.4700 (−5.74%) |
Oct 20, 2026 6d ago | Press Release | $0.4986 | awaiting T+20 | — | $0.4700 (−5.74%) |
Oct 14, 2026 12d ago | 8-K | $0.5382 | awaiting T+20 | — | $0.4700 (−12.67%) |
Oct 13, 2026 13d ago | 8-K | $0.4900 | awaiting T+20 | — | $0.4700 (−4.08%) |
Oct 6, 2026 20d ago | DEFA14A | $0.6000 | awaiting T+20 | — | $0.4700 (−21.67%) |
Oct 6, 2026 20d ago | DEF 14A | $0.6000 | awaiting T+20 | — | $0.4700 (−21.67%) |
Sep 29, 2026 27d ago | 8-K | $0.6745 | awaiting T+20 | — | $0.4700 (−30.32%) |
Sep 28, 2026 28d ago | 8-K | $0.6630 $0.4732 | ▼ −28.63% | ▼ −28.60% | $0.4700 (−29.11%) |
Sep 10, 2026 6w ago | 8-K | $0.7720 $0.5444 | ▼ −29.48% | ▼ −31.61% | $0.4700 (−39.12%) |
Jul 20, 2026 14w ago | 8-K | $0.8500 $0.8227 | ▼ −3.21% | ▼ −7.33% | $0.4700 (−44.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers